hhg logo
hygeia logo
hospital logo
mitera logo
general logo
lito logo
creta interclinic logo
alab
logimed
business care
health spot
digital clinic
Θεραπευτήριο Metropolitan Θεραπευτήριο Metropolitan
  • Ελληνικά
  • English
  • Home
  • About Us
    • About Metropolitan General
    • Testimonials
    • Our Vision & Mission
    • Scientific Committee
    • Quality & Safety
      • Certifications & Distinctions
      • Quality Policy
      • Complaints Submission Process
    • Human Resources
      • Training
      • Benefits
      • Career Opportunities
    • State of the art technology
    • Corporate Social Responsibility
  • Medical Services
    • General Services
      • Anesthesiology
      • Breast Center
      • Cardiac Surgery
      • Cardiology
      • Nutrition & Clinical Dietetics
      • Dermatology
      • Diabetes Center
      • E.N.T.
      • Endocrinology
      • Gastroenterology
      • General Surgery
      • Hematology
      • Hepatology
      • Internal Medicine
      • Interventional Cardiology
      • Advanced Interventional Endoscopy
      • Interventional Neuroradiology
      • Interventional Radiology
      • Medical Physics
      • Nephrology
      • Neurology
      • Neurosurgery
      • Oncology
      • Ophthalmology
      • Oral & Maxillofacial Surgery
      • Orthopedics
      • Physiotherapy
      • Plastic & Reconstructive Surgery
      • Pulmonology
      • Rheumatology
      • Robotic Surgery (Da Vinci)
      • Robotic Urology (Da Vinci)
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
    • Innovative Services
    • Specialized Units
      • Αcute Stroke Unit (ASU)
      • Hemodialysis Unit
      • Lithotripsy Unit
      • One Day Clinic (O.D.C)
      • Pathological Oncology Unit
      • Polyvalent Intensive Care Unit
    • Clinics & Special Departments
    • Laboratories
      • Anatomical Pathology
      • Bone Density Measurement
      • Breast Imaging
      • Bronchoscopic laboratory
      • Cardiac Catheterization Laboratory
      • Cardiology
      • Central Laboratories
      • CT-scan
      • Endoscopy Laboratory
      • Ιn - lab Sleep Study
      • X-Ray Laboratory
      • Neurophysiology Laboratory
      • Nuclear Medicine
      • ΜRI-Scan
      • Pulmonary Function Lab
      • Ultrasounds
      • Orthopantomogram
    • Outpatient Department
    • Check Up
      • Check Up BASIC
      • Check Up PLUS
      • Check Up Just For U Women
      • Check Up Just For U Men
      • Check Up Just For U Heart
      • Check Up Just For U Osteoporosis
      • Check Up Just For U Lipidemic Profil
      • Check Up Just For U Thyroid
      • Check Up Just For U Rheumatology
      • Check Up Just For U Diabetes
    • Emergency Department
    • Nursing
    • Αmbulances
    • Medical Tourism
    • Price List
  • Doctors
  • Information
    • Patients
      • Admission
      • Hospitalization
      • Discharge Procedure
      • Medical Records Office
    • Visitors
    • Access
    • Valet Parking
    • Insurance Companies
    • Social security funds
    • Health benefits for citizens
  • Media
    • Photos
    • Leaflets
  • Contact Us

Temos

 

  • CLINIC OF ONCOLOGIC
    CLINICAL STUDIES AND RESEARCH
  • CLINIC OF ONCOLOGIC
    CLINICAL STUDIES AND RESEARCH
  • Νοσοκομείο
  • Services
  • Clinics & Special Departments
  • Clinic of Oncologic Clinical Studies and Research

CLINIC OF ONCOLOGY MEDICAL STUDY AND INVESTIGATION

The Oncology Medical Study and Investigation Clinic aims at the provision of all standard or new, approved, innovative, targeted and personalized therapies in the field of oncology and the provision of authoritative research, diagnosis, approach and treatment methods in oncology issues, through cooperation with Metropolitan General Departments and Services, our Group Hospitals as well as university medical institutions/departments or oncology centers.

The Oncology Medical Study and Investigation Clinic was founded with the objective to deal with the needs of patients and their human environment facing oncology issues on a four-pillar basis:

  1. The availability of advisable, standard and internationally accepted diagnostic and treatment approaches to each disease.
  2. The participation in highly-renowned international oncology clinical studies.
  3. Early access to treatments demonstrated to be effective, even if not currently in circulation in our country, through free-o-charge early access programs.
  4. Participation in research programs such as the promotion or detection of benchmarks in the correct and effective choice of therapies.
INTERNATIONAL CLINICAL STUDIES

INTERNATIONAL CLINICAL STUDIES

Our Oncology Medical Study and Investigation Clinic participates in a significant number of clinical studies regarding patients suffering from metastatic prostate cancer, metastatic colorectal cancer, metastatic kidney cancer, bladder/urothelial cancer, microcytic (small-cell) lung cancer and other oncological diseases.

The Clinical Study Team consists of:

PRINCIPAL INVESTIGATOR

Evangelos Bournakis, Pathologist Oncologist, Director of the Oncology Medical Study and Investigation Clinic

SUB-INVESTIGATORS

Angeliki Sfika, Pathologist-Oncologist

Nikolaos Soupos, Pathologist-Oncologist

Nikoalos Skandalakis, Cardiologist

STUDY COORDINATOR

Athanasios Bournakis MSc, Chemical Engineer

STUDY NURSE

Stamatia Kotsia, Director of the Brief Hospitalization Department at Metropolitan General

What is a “clinical study”?

What is a “clinical study”?

A clinical study is a confirmation process of a medication already demonstrated to be effective and safe. The study medication is compared with a placebo (a pharmacological inactive substance) in case of (absence or presence of) any standard therapy in order to confirm whether this medication is more effective and may be approved for administration to the general public in everyday clinical practice.

In case an already standard treatment proven to benefit survival, the study compares the study medication with this standard treatment, first in relation to the standard therapy to the exclusion of anything else, and then adding a new medication to the standard treatment so that greater benefit for survival or response to the disease may be confirmed, in relation to the exclusive standard treatment.

What is the benefit to any patient by participating in a clinical study?

What is the benefit to any patient by participating in a clinical study?

The participation in clinical studies is connected to multiple advantages, usually guaranteeing a high level of treatment approach and monitoring through an internationally determined strict framework that specifies a protocol on an individual study basis.

The participation in clinical studies may yield the following results:

  1. Access to contemporary therapies combining internationally approved treatments through the addition of the new treatment regimens under study, without cost to the patient or his/her insurance company.
    The patient has access to hospital services covered by the study (blood tests, imaging, biopsies, brief hospitalizations, full in-patient hospitalizations and oncological monitoring by the study physicians) at no charge to the patient.
    Many times, depending on the clinical study, the patient may undergo free of any charges state-of-the-art imaging, laboratory or genetic controls, which being very expensive procedures are never covered by insurance funds.
    Furthermore, many international clinical studies cover transportation expenses charged to patients between the hospital and the patient’s residence, facilitating patient access from various parts in Greece to high-quality treatment centers, in a time of extreme financial difficulty.
  2. Patients may receive modern and promising treatments, before they become universally accessible, provided that such therapies demonstrate through the study procedure their therapeutic value attaining a complete cure in the end and improvement in the quality of life and overall survival.
    This is an exceptionally significant prospect especially for persons with often incurable, metastatic malignancies.
  3. Patients may receive therapies, in case the standard treatment choices are limited or exhausted.
  4. Persons with no insurance coverage may undergo the best possible approved therapies combined with the treatment under study in a high-quality hospital setting, free of charge.

Participation in a clinical study may be advisable only in case such study is the best possible solution to the treatment of the disease, after complete and detailed information to the person concerned. Such participation is always voluntary. At the same time it is not binding on anyone even after the participant initially accepted in writing to participate in such study. Any discontinuation of further participation is at the discretion of the participant and/or his/her attending physician.

In international clinical studies the administration of medication and the paraclinical examinations regarding the protocol are free, at no charge to the insurance carrier.

EARLY ACCESS PROGRAMS

EARLY ACCESS PROGRAMS

The early access programs involve new medication treatments with demonstrated benefits in the targeted treatment of malignancies, approved by the FDA in the USA and/or by EMA in Europe; however, they are not yet currently in circulation in Greece since they have not been ascribed a price.
Access to these medications is possible through these programs, a long time prior to their pricing and prescription, offering their benefits from an early time to patients in need without any charge to them (in some case without even a charge to their insurance agency as it is made freely available by the pharmaceutical company producing it; however, this case applies to a very minimal number of patients).

The early access programs are not clinical studies.

At this stage there is no active early access program in our Clinic.

  • Early access program for non-metastatic castration-resistant prostate cancer. Free administration and access to apalutamide to non-metastatic castration-resistant prostate cancer. (This program is now completed).
  • Early access program for microcytic lung cancer – extensive disease, first-line study.
  • Free administration/ access to atezolizumab to already established chemotherapy treatment with etoposide and platinum.

(This program is now completed. The medication is already available by the National Organization for Health Care Services EOPYY)

RESEARCH PROGRAMS

RESEARCH PROGRAMS

Prognostic and predictive value of tumor molecular alteration in patients with prostate cancer TR_9/2.

(Approval of the Hospital Scientific Board is pending for administration of the program to prostate cancer patients)

How can I get information on availability of a clinical study, an early access program or any research program that may be appropriate for my case?

How can I get information on availability of a clinical study, an early access program or any research program that may be appropriate for my case?

You may search the Metropolitan Hospital site or the Oncology Medical Study and Investigation Clinic site, the clinical studies, the early access programs or research programs, which are active in this phase or are expected to be activated. You may then communicate with the Clinic oncologists and arrange for an appointment regarding the prospect of induction into any of the available schemes, depending on the nature of your problem.

In case you are already attended by a physician, either s/he may be informed concerning the value of clinical studies and discuss such participation matters with you or refer you to any member of our Team at the Oncology Medical Study and Investigation Clinic.

  • Head and neck cancer
  • Central nervous system (CNS) cancer
  • Gynecological (GY) cancer (ovaries, uterus/endometrium, uterine cervix)
  • Breast cancer
  • Genitourinary cancer (prostate, kidney, urothelial cases

*In this present conjuncture of the COVID-19 pandemic, for the most effective protection of all of us, you may also contact us for any questions and queries you may have regarding the clinical studies, early access programs, or research programs that are in progress in the Clinic at our email address: OncoCTR.Clinic@yahoo.com

PROSTATE CANCER

PROSTATE CANCER

Clinical Study Phase 3: PRESIDE

This is a study for the evaluation of the treatment benefits with enzalutamide after disease onset in males starting treatment with dosetaxel after exacerbation of castration-resistant metastatic prostate cancer, while exclusively receiving enzalutamide (September 2015).

(The process of patient induction is now completed)

Clinical Study CO39385

Phase 3, polycentric, randomized, placebo-controlled, double-blind study with atezolizumab combined with enzalutmaide compared with enzalutamide exclusively in patients with castration-resistant metastatic prostate cancer after failure of treatment with androgen biosynthesis inhibitors and failure or inability or denial of treatment with chemotherapy scheme with taxane. (October 2017: This study is now completes)

Clinical Study CO39303

Phase 3, randomized, double-blind, placebo-controlled, polycentric study for the treatment with ipatasertib plus abiterone plus prednisone/prednizolone, in relation with treatment with placebo plus abiterone plus prednisone/prednizolone, to patients with asymptomatic or moderately symptomatic castration-resistant metastatic prostate cancer who have not received any other treatment before (November 2017-). (The process of patient induction is now completed)

Study CONTACT-02_XL184-315

Phase 3, randomized, study administration of cabozantinib combined with atezolizumab compared with second hormonal agent (enzalutamib or abiterone) to high-risk patients suffering from castration-resistant metastatic prostate cancer.
(In anticipation of the study activation and the Center)

KIDNEY CANCER

KIDNEY CANCER

Non-Invasive Study CPZ034AGR06 Atlas

Prospective observation study, Phase 4 to patients with advanced renal cell carcinoma for the evaluation of the effectiveness and the duration of responses to first-line therapy with pazopanib. (This study is now completed)

BLADDER CANCER – UROTHELIAL CANCER

BLADDER CANCER – UROTHELIAL CANCER

Clinical Study CA017-78

Phase 3, randomized study of introductory exclusive chemotherapy compared with introductory chemotherapy combined with nivolumab or with nivolumab plus BMS-986205, followed by continued post-operative treatment with nivolumab or nivolumab plus BMS-986205 to patients with non-penetrating bladder cancer.  (This study starts in September 2020. Induction of patient continues. Active study)

Digestive system cancers: Stomach, colorectal and pancreas cancers (GI cancers)

LARGE INTESTINE/ COLORECTAL CANCER

LARGE INTESTINE/ COLORECTAL CANCER

Clinical Study ISO-CC-007
Randomized, polycentric, parallel group study, Phase 3 for the comparison of effectiveness of arfolitixorin compared with leucovorin combined with 5-fluouroacil, oxaliplatin and bevacizumab on patients with advanced colorectal cancer (first-line treatment). (This study is active and patient induction continues)

Clinical Study CA209-8HW

Phase 3b, randomized clinical study of monotherapy with nivolumab compared with combination of nivolumab and ipilimumab or chemotherapy of the research physician’s choice on patients with metastatic colorectal cancer and microsatellite instability (MSI-H or d MMR. (This study involves patients on first-line therapy or any other line of therapy – multiple therapy patients). (This study is active and patient induction continues)

Small-cell (microcytic or non-microcytic) lung cancer

MICROCYTIC LUNG CANCER

MICROCYTIC LUNG CANCER

Clinical Study GO41767

This is a Phase 3, randomized, double-blind, placebo-controlled comparison study of a therapy with atezolizumab and carboplatin and etoposide with or without tiragolumab (anti-TIGIT antibody) to patients with extensive-stage microcytic lung cancer who have never received any other treatment. (This study is active and patient induction continues)

 

Staff

Chief: Evangelos Bournakis, Oncologist

Associates:
Aggeliki Sfika, Oncologist
Nikolaos Soupos, Oncologist
Nikolaos Skandalakis, Cardiologist

 

Contact number: +30 210 650 2831

 

  • Share
  • Tweet
  • Share
  • Share
General Services
Anesthesiology
Breast Center
Cardiac Surgery
Cardiology
Nutrition & Clinical Dietetics
Dermatology
Diabetes Center
E.N.T.
Endocrinology
Gastroenterology
General Surgery
Hematology
Hepatology
Internal Medicine
Interventional Cardiology
Advanced Interventional Endoscopy
Interventional Neuroradiology
Interventional Radiology
Medical Physics
Nephrology
Neurology
Neurosurgery
Oncology
Ophthalmology
Oral & Maxillofacial Surgery
Orthopedics
Physiotherapy
Plastic & Reconstructive Surgery
Pulmonology
Rheumatology
Robotic Surgery (Da Vinci)
Robotic Urology (Da Vinci)
Thoracic Surgery
Urology
Vascular Surgery
Innovative Services
Heart MRI
Robotic Gynecology
Specialized Units
Αcute Stroke Unit (ASU)
Hemodialysis Unit
Lithotripsy Unit
One Day Clinic (O.D.C)
Pathological Oncology Unit
Polyvalent Intensive Care Unit
Clinics & Special Departments
Laboratories
Anatomical Pathology
Bone Density Measurement
Breast Imaging
Bronchoscopic laboratory
Cardiac Catheterization Laboratory
Cardiology
Central Laboratories
CT-scan
Endoscopy Laboratory
Ιn - lab Sleep Study
X-Ray Laboratory
Neurophysiology Laboratory
Nuclear Medicine
ΜRI-Scan
Pulmonary Function Lab
Ultrasounds
Orthopantomogram
Outpatient Department
Check Up
Check Up BASIC
Check Up PLUS
Check Up Just For U Women
Check Up Just For U Men
Check Up Just For U Heart
Check Up Just For U Osteoporosis
Check Up Just For U Lipidemic Profil
Check Up Just For U Thyroid
Check Up Just For U Rheumatology
Check Up Just For U Diabetes
Emergency Department
Nursing
Αmbulances
Medical Tourism
Price List

SEE ALSO

PrevNext
ABOUT METROPOLITAN GENERAL
Metropolitan General, one of the largest and most excellently equipped healthcare units in Greece, has...
ABOUT METROPOLITAN...
AMBULANCES
Approved by the Greek National Center of Emergency Care (EKAV), Metropolitan General’s ultramodern ambulances are...
AMBULANCES
EMERGENCY DEPARTMENT
The Emergency Department at Metropolitan General operates on a 24-hour basis and immediately and effectively...
EMERGENCY DEPARTME...
MEDICAL TOURISM
Metropolitan General accommodates a special International Patient Department aiming to the best possible service and...
MEDICAL TOURISM
QUALITY POLICY
The Management of Metropolitan General, acknowledging that proper medical diagnosis, healthcare and treatment of patients...
QUALITY POLICY
OUTPATIENT DEPARTMENT
Responsible and comprehensive treatment-care of all medical cases (internal medicine, surgery, cardiology, orthopedics, etc.) staffed...
OUTPATIENT DEPARTM...
OUR VISION & MISSION
Today, Metropolitan General is a pioneer hospital that does not consider the provision of high-quality...
OUR VISION & MISSI...
INNOVATIVE SERVICES
INNOVATIVE SERVICE...
CHECK UP
Placing great emphasis on prevention, Metropolitan General accommodates a well equipped and fully organized Check-up...
CHECK UP

Νοσοκομείο Metropolitan

Book your appointment online quickly and easily!

REQUEST AN APPOINTMENTPRICE LIST

GIVING IT

ALL FOR

YOUR HEALTH

ΣΥΝΔΕΣΗ/ΑΠΟΣΥΝΔΕΣΗ

© 2021 Metropolitan General
Web Design by CnC Tech & Ruler

ADDRESS

264 Mesogion Avenue

GR-15562 Holargos

EMERGENCY (24/7)

CALL CENTER 210 6502000

AMBULANCE 210 6502627

APPOINTMENT

infogeneral@metropolitan-hospital.gr

TELEPHONE 210 6502000

CERTIFICATIONS

      preferred partner 2020Quality in International Care  ISO 9001  iso9001 s COEHS

OFFICIAL SPONSOR

AEK BC logoOlympic Winners logo